Carbon Ion Radiation Therapy of Sacrococcygeal Chordomas: A Comparison of Different Fractionation Schemes.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42541495.
- Also identified by DOI 10.1016/j.ijrobp.2026.06.3081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sacrococcygeal chordomas are rare, radioresistant malignant bone tumors that are challenging to treat with conventional photon therapy. Carbon ion radiation therapy (CIRT) offers a favorable dose distribution and higher biological effectiveness, which may improve local control. This retrospective study from the Heidelberg Ion-Beam Therapy Center compares 2 carbon ion fractionation schemes for sacrococcygeal chordomas. The study included 157 patients treated between 2011 and 2025 with CIRT with either 64 GyRBE in 16 fractions of 4 GyRBE each (96.0 Gy EQD2) or 66 GyRBE in 22 fractions of 3 GyRBE each (82.5 Gy EQD2). Outcomes analyzed were local progression-free survival (LPFS), distant metastasis-free survival, overall survival (OS), and toxicity. Survival curves were analyzed using the Kaplan-Meier method, and sacral insufficiency fractures were evaluated with a competing risk analysis. Multivariable Cox regression was used to identify independent risk factors associated with local recurrence and OS. At 2 and 4 years, LPFS was 83.4% and 71.8% for the 64 GyRBE in 16 fractions group with a median LPFS of 58 months (95% CI, 39.8-76.2 months) versus 71.8% and 52.3% for the 66 GyRBE in 22 fractions group with a median LPFS of 53 months (95% CI, 35.0-71.0 months); the difference was not statistically significant (P = .140). In multivariable analysis, female sex (HR, 2.44; 95% CI, 1.46-4.08; P < .001) and treatment for recurrent disease (HR, 3.01; 95% CI, 1.49-6.06; P = .002) were independent predictors of local progression. OS at 2 and 4 years was 96.5% and 85.4% for 16 × 4 GyRBE versus 98.6% and 91.2% for 22 × 3 GyRBE, with no significant difference (P = .816). A larger clinical target volume was associated with worse OS. Sacral insufficiency fractures occurred more frequently after 16 × 4 GyRBE (47% vs 24%; P = .003). For sacrococcygeal chordomas treated with CIRT, the 2 regimens showed no significant difference in LPFS or OS, despite a slight numerical advantage of the 64 GyRBE in 16 fractions in LPFS. However, the 64 GyRBE in 16 fractions regimen was associated with a significantly higher rate of insufficiency fractures.